Miguel Areia

ORCID: 0000-0001-9787-8175
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Screening and Detection
  • Helicobacter pylori-related gastroenterology studies
  • Gastrointestinal disorders and treatments
  • Esophageal and GI Pathology
  • Esophageal Cancer Research and Treatment
  • Colorectal Cancer Surgical Treatments
  • Gastrointestinal Tumor Research and Treatment
  • Gastroesophageal reflux and treatments
  • Pancreatic and Hepatic Oncology Research
  • Radiomics and Machine Learning in Medical Imaging
  • Genetic factors in colorectal cancer
  • Image Retrieval and Classification Techniques
  • Metastasis and carcinoma case studies
  • Medical Device Sterilization and Disinfection
  • Eosinophilic Esophagitis
  • AI in cancer detection
  • Pancreatitis Pathology and Treatment
  • Dysphagia Assessment and Management
  • Neuroendocrine Tumor Research Advances
  • Head and Neck Cancer Studies
  • Colorectal and Anal Carcinomas
  • Gastrointestinal Bleeding Diagnosis and Treatment
  • Clinical Nutrition and Gastroenterology
  • Diverticular Disease and Complications

Instituto Português de Oncologia de Coimbra Francisco Gentil
2008-2025

Instituto Português de Oncologia Francisco Gentil
2016-2025

Universidade do Porto
2016-2025

IPO Porto
2025

Centre for Health Technology and Services Research
2011-2021

RELX Group (Netherlands)
2020

Technologies pour la Santé
2014

Sociedade Portuguesa de Cardiologia
2014

University of Coimbra
2006-2010

Hy-Line (United States)
2008

Main Recommendations Patients with chronic atrophic gastritis or intestinal metaplasia (IM) are at risk for gastric adenocarcinoma. This underscores the importance of diagnosis and stratification these patients. High definition endoscopy chromoendoscopy (CE) is better than high white-light alone this purpose. Virtual CE can guide biopsies staging metaplastic changes target neoplastic lesions. Biopsies should be taken from least two topographic sites (antrum corpus) labelled in separate...

10.1055/a-0859-1883 article EN Endoscopy 2019-03-06

Atrophic gastritis, intestinal metaplasia, and epithelial dysplasia of the stomach are common associated with an increased risk for gastric cancer. In absence guidelines, there is wide disparity in management patients these premalignant conditions. The European Society Gastrointestinal Endoscopy (ESGE), Helicobacter Study Group (EHSG), Pathology (ESP) Sociedade Portuguesa de Endoscopia Digestiva (SPED) have therefore combined efforts to develop evidence-based guidelines on precancerous...

10.1055/s-0031-1291491 article EN Endoscopy 2011-12-23

Artificial intelligence (AI) tools increase detection of precancerous polyps during colonoscopy and might contribute to long-term colorectal cancer prevention. The aim the study was investigate incremental effect implementation AI in screening on incidence mortality, cost-effectiveness such tools.We conducted Markov model microsimulation using with without for individuals at average risk (no personal or family history cancer, adenomas, inflammatory bowel disease, hereditary syndrome). We ran...

10.1016/s2589-7500(22)00042-5 article EN cc-by The Lancet Digital Health 2022-04-13

Abstract This ESGE Position Statement defines the expected value of artificial intelligence (AI) for diagnosis and management gastrointestinal neoplasia within framework performance measures already defined by ESGE. is based on clinical relevance task preliminary evidence regarding in or settings. Main recommendations: (1) For acceptance AI assessment completeness upper GI endoscopy, adequate level mucosal inspection with should be comparable to that assessed experienced endoscopists. (2)...

10.1055/a-1950-5694 article EN Endoscopy 2022-10-21

<b>Background and study aim: </b>The reliability external validity of narrow band imaging (NBI) in the stomach have not been described consistently. The aim current was to describe estimate accuracy a simplified classification system for NBI diagnosis gastric lesions. <b>Methods: </b>Consecutive patients undergoing endoscopy at two reference centers (n = 85, 33 % with dysplasia) were included studies. In total, 224 different areas biopsied recorded onto video. derivation study, previously...

10.1055/s-0031-1291537 article EN Endoscopy 2012-01-31

Summary of statements In Europe at present, but also in 2040, 1 3 cancer-related deaths are expected to be caused by digestive cancers. Endoscopic technologies enable diagnosis, with relatively low invasiveness, precancerous conditions and early cancers, thereby improving patient survival. Overall, endoscopy capacity must adjusted facilitate both effective screening programs rigorous control the quality assurance surveillance systems required. For average-risk populations, ESGE recommends...

10.1055/a-1104-5245 article EN Endoscopy 2020-02-12

Endoscopic screening for gastric cancer is debatable in countries with an intermediate risk.The objective of this article to determine the cost-utility strategies a European country.We conducted analysis using Markov model comparing three versus no screening: stand-alone upper endoscopy, endoscopy combined colorectal colonoscopy after positive faecal occult blood test or pepsinogens serologic screening. Clinical data were collected from systematic reviews, costs published national and...

10.1177/2050640617722902 article EN United European Gastroenterology Journal 2017-07-20

INTRODUCTION: The safety of Helicobacter pylori eradication treatments and to what extent adverse events (AEs) influence therapeutic compliance in clinical practice are hardly known. Our aim was assess the frequency, type, intensity, duration AEs, their impact on compliance, for most frequently used “European Registry management.” METHODS: Systematic prospective noninterventional registry European gastroenterologists (27 countries, 300 investigators) management H. infection routine practice....

10.14309/ajg.0000000000001246 article EN The American Journal of Gastroenterology 2021-04-08

There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks to a three-in-one single-capsule formulation.To evaluate effectiveness safety therapy.Data were collected multicentre, prospective registry clinical practice gastroenterologists on management H. infection, where patients registered at Asociación Española de Gastroenterologia REDCap database an electronic case...

10.1177/2050640620972615 article EN cc-by-nc-nd United European Gastroenterology Journal 2020-11-12

Background Progression of extensive gastric premalignant conditions to cancer might warrant surveillance programms. Recent guidelines suggest a 3‐yearly endoscopic follow‐up for these patients. Our aim was determine the cost utility patients with such as atrophy or intestinal metaplasia. Materials and Methods A cost‐utility economic analysis performed from societal perspective in Portugal using Markov model compare two strategies: versus no surveillance. Clinical data were collected...

10.1111/hel.12150 article EN Helicobacter 2014-08-28

<b>Background and study aim</b> Upper endoscopy is the most common method for diagnosis of upper gastrointestinal tract diseases. The aim this was to determine whether premedication with simethicone or <i>N</i>-acetylcysteine improves mucosal visualization during endoscopy. <b>Patients methods</b> This a randomized, double-blind, placebo-controlled 297 patients scheduled who were premedicated 15 – 30 minutes before procedure with: 100 mL water (placebo, group A); plus mg (group B); 600 C)....

10.1055/s-0042-119034 article EN Endoscopy 2016-11-16

Main Recommendations At a population level, the European Society of Gastrointestinal Endoscopy (ESGE), Helicobacter and Microbiota Study Group (EHMSG), Pathology (ESP) suggest endoscopic screening for gastric cancer (and precancerous conditions) in high-risk regions (age-standardized rate [ASR] &gt; 20 per 100 000 person-years) every 2 to 3 years or, if cost–effectiveness has been proven, intermediate risk (ASR 10–20 5 years, but not low-risk &lt; 10). ESGE/EHMSG/ESP recommend that...

10.1055/a-2529-5025 article EN other-oa Endoscopy 2025-03-20
Coming Soon ...